The report of Global Anti-Obesity Prescription Drugs market by Drug Type (Contrave, Belviq, Xenical, Saxenda, Qsymia), Type (Prescription Drugs, OTC Drugs), Drug class (Peripherally Acting Anti-obesity Drugs, Centrally Acting Anti-obesity Drugs), Sales channel (Direct Channel, Distribution Channel), Application (Hospitals Pharmacies, Retail Pharmacies, E-commerce) and Region (Asia Pacific, North America, Europe, Latin America, and Middle East Africa) is expected to reach US$ XX Bn by 2026, at a CAGR of XX% during a forecast period.
Obesity means having too much body fat. According to World Health Organization reveals that global obesity has more than doubled than 1980. In percentage-wise an estimated that 39% of adults were overweight and 14% were obese in 2015. Based on surveys conducted by the Centers for Disease Control and Prevention, a shocking 68.8% of the U.S. adult population is considered to be overweight. The FDA has approved five Anti-Obesity Prescription Drugs such as orlistat (Xenical, Alli), lorcaserin (Belviq), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and liraglutide (Saxenda) for long-term use.
Saxenda Drugs segment is expected to grow at the highest XX% CAGR during the forecast period.
Global Anti-Obesity Prescription Drugs Market segmented on the basis of drug type such as Contrave, Belviq, Xenical, Saxenda, and Qsymia. Xenical was the largest vending drug in the market till 2012. Still, recently permitted Saxenda by Novo Nordisk Pharma companies is gaining large interest between obese people and is increasing at a fast growth rate. They launched Saxenda in all the major markets with a higher concentrated dose of glucagon like peptide-1 (GLP-1) receptor agonist, liraglutide, which was first developed for type 2 diabetes as Victoza. Dual therapy for obesity and type 2 diabetes is the modern trend in the market.
The North America dominated the Global Anti-Obesity Prescription Drugs Market in 2018
North America is expected to emerge as a leading region in the global anti-obesity prescription drugs market during the forecast period. Because of the awareness of obesity among the population and the risks associated with the health situation have resulted in the anti-obesity prescription drugs market describing flourished growth in the region over the years. Furthermore, the Asia Pacific market for anti-obesity prescription drugs is anticipated to drive in the coming years, thanks to the rise in obese population. India and China are set to be the most attractive destinations owing to the large unused market.
Key players operating the Global Anti-Obesity Prescription Drugs market are F Hoffmann La Roche, Arena Pharmaceuticals, Orexigen Therapeutics, Phentermine and Topiramate, VIVUS, Inc, Liraglutide, Bupropion and Naltrexone, Orlistat, Bupropion and Naltrexone, Novo Nordisk, Lorcaserin, GlaxoSmith Kline, Eisai Co, Ltd, Boehringer Ingelheim, Merck & Co, Pfizer, Rhythm Pharmaceuticals, Zafgan, Takeda Pharmaceuticals and Novo Nordisk.
Maximize Market Research, a global market research firm with a dedicated team of specialists and data has carried out extensive research about the Global Anti-Obesity Prescription Drugs market. The report encompasses the market by different segments and region, providing an in-depth analysis of the overall industry ecosystem, useful for making an informed strategic decision by the key stakeholders in the industry. Importantly, the report delivers forecasts and share of the market, further giving an insight into the market dynamics, and future opportunities that might exist in the Global Anti-Obesity Prescription Drugs market. The driving forces, as well as considerable restraints, have been explained in depth. in addition to this, competitive landscape describing the strategic growth of the competitors have been taken into consideration for enhancing market know-how of our clients and at the same time explain Global Anti-Obesity Prescription Drugs market positioning of competitors.
Browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on “Global Anti-Obesity Prescription Drugs Market”
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
Omkar Heights,
ManikBaug, Vadgaon Bk,
Sinhagad Road, Pune – 411051, Maharashtra, India.
+91 9607195908